NCT06699355View on ClinicalTrials.gov

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

December 29, 2023

Study Completion Date

December 29, 2023

Conditions
Healthy
Interventions
DRUG

Enlicitide Decanoate

Oral administration

DRUG

Atorvastatin

Oral administration

Trial Locations (1)

68502

Celerion (Site 0001), Lincoln

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06699355 - A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024) | Biotech Hunter | Biotech Hunter